"10.1371_journal.pone.0023931","plos one","2011-09-01T00:00:00Z","Karsten Weller; Claudia Ziege; Petra Staubach; Knut Brockow; Frank Siebenhaar; Karoline Krause; Sabine Altrichter; Martin K Church; Marcus Maurer","Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany; Department of Dermatology, Universitätsmedizin Mainz, Mainz, Germany; Department of Dermatology and Allergy Biederstein, Technische Universität, München, Germany","Conceived and designed the experiments: KW CZ FS KK SA MM. Analyzed the data: KW CZ MKC MM. Wrote the paper: KW CZ MKC MM. Acquisition of data: KW CZ PS KB FS KK SA MM. Critical revision of the manuscript for important intellectual content: All authors. Final approval of the manuscript: All authors.","The authors have read the journals policy and have the following conflicts. This work was supported by Essex Pharma (now MSD). KW: The author declares that he is or recently was involved in clinical trials supported by Essex Pharma (now MSD) and was compensated for educational lectures by Essex Pharma (now MSD), Novartis, Shire and UCB. PS: The author declares that he is or recently was involved in clinical trials supported by Essex Pharma (now MSD) and was compensated for educational lectures by Essex Pharma (now MSD), Novartis and Shire. FS: The author declares that he was previously involved in clinical trials supported by Essex Pharma (now MSD) and was compensated for educational lectures. KK: The author declares that she was compensated for educational lectures by Novartis, Dr. Pfleger, Shire and received a travel grant from Regeneron Pharmaceuticals. MKC: The author declares that he has received honoraria for lectures or consulting from UCB Pharma, Glaxo Smith Kline, Aventis, FAES Pharma and Schering Plough. MM: The author declares that he is or recently was a speaker and/or advisor for Almirall Hermal, Bayer Schering Pharma, Biofrontera, Essex Pharma, Genentech, JADO Technologies, Jerini, Merckle Recordati, Novartis, Sanofi Aventis, Schering-Plough, Leo, MSD, Merck, Shire, Symbiopharm, UCB, and Uriach. None of the authors has patents or commercial interests in products in development or marketed products to declare. This does not alter their adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2011","09","Karsten Weller","KW",9,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
